SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Serdal Korkmaz, Mehmet Sinan Dal, Ilhami Berber, Deniz Goren Sahin, Mehmet Hilmi Dogu, Orhan Ayyildiz, Ilknur Nizam, Murat Albayrak, Ramazan Esen, Sinem Namdaroglu, Mehmet Sencan, Olga Meltem Akay, Sibel Hacioglu, Rahsan Yildirim, Ali Eser, Anil Tombak, Cigdem Pala, Osman Ilhan, Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study, Geriatrics & Gerontology International, 2015, 15, 2
  2. 2
    Dianne Pulte, Maria Theresa Redaniel, Jenny Bird, Mona Jeffreys, Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century, European Journal of Haematology, 2015, 94, 3
  3. 3
    Wael Maharsy, Anne Aries, Omar Mansour, Hiba Komati, Mona Nemer, Ageing is a risk factor in imatinib mesylate cardiotoxicity, European Journal of Heart Failure, 2014, 16, 4
  4. 4
    Fermín Sánchez-Guijo, Elderly CML patients’ treatment: Considering not only physician's judgment but also co-morbidity indexes, Leukemia Research, 2014, 38, 10, 1156

    CrossRef

  5. 5
    Gabriele Gugliotta, Fausto Castagnetti, Michela Apolinari, Sara Pirondi, Michele Cavo, Michele Baccarani, Gianantonio Rosti, First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies, Drugs, 2014, 74, 6, 627

    CrossRef

  6. 6
    Bjørn Tore Gjertsen jr., Mot en mer spesifikk kreftbehandling?, Tidsskrift for Den norske legeforening, 2014, 134, 10, 1017

    CrossRef

  7. 7
    Ulrike Proetel, Nadine Pletsch, Michael Lauseker, Martin C. Müller, Benjamin Hanfstein, Stefan W. Krause, Lida Kalmanti, Annette Schreiber, Dominik Heim, Gabriela M. Baerlocher, Wolf-Karsten Hofmann, Elisabeth Lange, Hermann Einsele, Martin Wernli, Stephan Kremers, Rudolf Schlag, Lothar Müller, Mathias Hänel, Hartmut Link, Bernd Hertenstein, Markus Pfirrmann, Andreas Hochhaus, Joerg Hasford, Rüdiger Hehlmann, Susanne Saußele, Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV, Annals of Hematology, 2014, 93, 7, 1167

    CrossRef

  8. 8
    Mario Tiribelli, Marta Medeot, Overcoming therapy failure in elderly patients with chronic myeloid leukemia, International Journal of Hematologic Oncology, 2014, 3, 5, 353

    CrossRef

  9. 9
    Gabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, Michele Cavo, Michele Baccarani, Gianantonio Rosti, Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors, Expert Review of Hematology, 2013, 6, 5, 563

    CrossRef

  10. 10
    Andrew M. Brunner, Federico Campigotto, Hossein Sadrzadeh, Benjamin J. Drapkin, Yi-Bin Chen, Donna S. Neuberg, Amir T. Fathi, Trends in all-cause mortality among patients with chronic myeloid leukemia, Cancer, 2013, 119, 14